Siponimod is a second-generation oral sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration (FDA) in March 2019 for the treatment of relapsing types of multiple sclerosis (MS), including “active” secondary progressive MS (SPMS).1 The phenotypic subtypes of MS are defined by their clinical course.2 Most patients initially exhibit…
Asaff Harel, MD
https://www.doximity.com/profiles/af13b05e-c0c6-43f8-97af-68ccb44fa9be
Asaff Harel, MD, MSc, is a board-certified attending neurologist specializing in Neuroimmunology and Multiple Sclerosis at the Northwell Health Multiple Sclerosis Center at Lenox Hill Hospital, which is part of Northwell Health’s Institute for Neurology and Neurosurgery. Dr Harel received his medical degree from the University of Pittsburgh School of Medicine, where he was elected a member of the Gold Humanism Honor Society and a Howard Hughes Medical Institute Fellow. He completed a neurology residency and a multiple sclerosis fellowship at Mount Sinai Hospital, funded by the National Multiple Sclerosis Society Institutional Clinical Training Award and the National Institutes of Health. Dr Harel has extensive research experience. His current research focuses on investigating the use of advanced MRI techniques to monitor disease worsening in relapsing remitting and primary progressive multiple sclerosis.
